← Back

Wire · opportunities

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

Published

10 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ascopost.com →

◆ Verified

Fusion42 · 10 September 2026 · Fusion42 review

The FDA approved daraxonrasib, a first-in-class targeted oral therapy for metastatic pancreatic adenocarcinoma, based on phase III trial data showing a near doubling of median overall survival in treated patients. The drug received Breakthrough Therapy, Orphan Drug designations, and Priority Review, highlighting accelerated regulatory pathways for serious oncology treatments.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

The FDA’s early approval signals faster regulatory routes for novel cancer treatments. If you are building targeted oncology drugs, now’s the time to engage FDA programs to speed your path to market.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancertargeted-therapybreakthrough-therapyoncology